NEW YORK--(BUSINESS WIRE)--Pragma Pharmaceuticals is pleased to announce that it is planning the launch of Decadron® (dexamethasone) .5, .75, 4 and 6 mg tablets in early 2018.
Fera Pharmaceuticals will manage the sales and marketing of the product for Pragma.
Decadron has been a staple for decades in physician offices across the United States and is one of the most widely used steroids due to its effectiveness and potency.
Decadron (dexamethasone tablets, USP) is a first-generation adrenocortical steroid which has a range of indications, including: allergic states, dermatologic states, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic disorders, nervous system disorders, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders. More information and full prescribing information are available at www.ferapharma.com.
About Fera Pharmaceuticals
Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. For more information visit www.ferapharma.com.
Decadron® is a registered trademark of Pragma Pharmaceuticals